

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT		Docket Number: 1662/61003			
Application Number 10/646059	Filing Date August 21, 2003	Examiner	Art Unit Not yet assigned		
Invention Title A METHOD FOR THE PURIFICATION OF LANSOPRAZOLE		Inventors Claude SII	Inventors Claude SINGER et al.		

Address to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: 2/18/04

Reg. No. 46,877

Signature: ___

Sir:

- 1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
- 2. A concise explanation of the relevance of the following non-English language references is found in the specification:

ES 2,063,705 ES 2,105,953

- A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
- 4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit

Account No. 11-0600 for such fees. A copy of this communication is enclosed for charging purposes.

Dated: 2/18/64

By:

Siu K. Lo (Reg. No. 46,877)

KENYON & KENYON One Broadway New York, N.Y. 10004 (212) 425-7200 (telephone) (212) 425-5288 (facsimile)

CUSTOMER NUMBER 26646



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

Docket Number: 1662/61003

Application Number 10/646059

Filing Date

August 21, 2003

Examiner

Art Unit

Not yet assigned

Invention Title

A METHOD FOR THE PURIFICATION OF LANSOPRAZOLE

Inventors

Claude SINGER et al.

Address to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

I hereby certify that this correspondence is being deposited

Date: 2/18/04

Reg. No. 46,877

Signature: Wohlkoff

Sir:

- 1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
- 2. A concise explanation of the relevance of the following non-English language references is found in the specification:

ES 2,063,705

ES 2,105,953

- A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
- 4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit

Account No. 11-0600 for such fees. A copy of this communication is enclosed for charging purposes.

Dated: 2/18/64

By:

Siu K. Lo (Reg. No. 46,877)

KENYON & KENYON One Broadway New York, N.Y. 10004 (212) 425-7200 (telephone) (212) 425-5288 (facsimile)

CUSTOMER NUMBER 26646

FORMATION DISCLOSURE STATEMENT
BY APPLICANT

FEB 2 0 2004 TO

FEB 2 0 2004 TO

ATTY. DOCKET NO. 1662/61003 SERIAL NO. 10/464,059

APPLICANT

Claude SINGER et al.

FILING DATE

August 21, 2003 GROUP

Not Yet

Assigned

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PUBLICATION NUMBER	PUBLICATION DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	4,628,098	Dec. 9, 1986	Nohara et al.		
-	4,689,333	Aug. 25, 1987	Nohara et al.		
	5,026,560	June 25, 1991	Makino et al.		
	5,045,321	Sept. 3, 1991	Makino et al.		
	5,093,132	Mar. 3, 1992	Makino et al.		
	5,433,959	July 18, 1995	Makino et al.		ė.
	5,578,732	Nov. 26, 1996	Kato et al.		
	6,002,011	Dec. 14,1999	Kato et al.		
***	6,166,213	Dec. 26, 2000	Anousis et al.		
	6,180,652 B1	Jan. 30, 2001	Tsujii et al.		
	6,268,502 B1	July 31, 2001	Milac et al.		
	6,313,303 B1	Nov. 6, 2001	Tagami et al.		

FOREIGN PATENT DOCUMENTS

EVALUED.	500,1115115	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION	
EXAMINER INITIAL	DOCUMENT NUMBER				YES	NO
	2 063 705	January 1, 1995	ES			
	2 105 953	October 16, 1997	ES			
:	WO 99/47514	Sept. 23, 1999	wo			
	WO 01/21617 A1	29 March 2001	wo			
	WO 01/68594 A1	20 Sept. 2001	wo		Abst.	



OTHER DOCUMENTS

EXAMINER	TRADEMA		
INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.		
	The United States Pharmacopeial Convention, Inc., Pharmacopeial Forum Vol. 26 No. 5., pp. 1229 -1232.; 2000.		
Drug Development and Industrial Pharmacy "Stabilization of a New Antiulcer Drug (Lansoprazole) in the Solid Dosage Forms, pp. 1437-1447, 1992.			
EXAMINER	DATE CONSIDERED		
FXAMINER: Initial	if citation is considered, whether or not citation is in conformance with M.P.F.P. 609:		

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with M.P.E.P. 609; strike out citation if not in conformance and not considered. Include copy of this form with next communication to applicant.